Also found in: Dictionary, Wikipedia.
Related to Herceptin: HER2


A monoclonal antibody used in treating her 2 neu-positive carcinoma of breast.
Synonym(s): transluzumab


A trademark for the drug trastuzumab.


Trastuzumab Molecular oncology A humanized monoclonal antibody to the HER-2 growth factor receptor used to treat metastatic breast CA that overexpresses HER-2. See Breast cancer, Monoclonal antibody.


A brand name for the monoclonal antibody drug TRASTUZUMAB.


A brand name for TRASTUZUMAB.

Patient discussion about Herceptin

Q. Can anyone tell me about herceptin? Can anyone tell me about herceptin? What kind of treatment it is and why it’s popular? Who can be treated? Does it have any side effects?

A. It is a monoclonal antibody. Patients somewhere between 15 – 25 % with breast cancer responded well to this treatment. The patients have in their cancer cells a large amount of a protein called HER2. The treatment for breast cancer patient will depend on the stage of cancer. Side effects of this Herceptin also called trastuzumab are Fatigue, diarrhea, pain, heart problems and reaction to the drug - causing chills, fever and possibly an itchy rash, feeling sick, breathlessness, wheezing, a headache, flushes and faintness. This happens to about half of patients with the first treatment but usually wears off with further treatments.

Q. What side effects are possible with chemotherapy and herceptin? My sister is taking chemotherapy now. Earlier the doctors prescribed herceptin and she had very severe vomiting and anemia. What side effects are possible with chemotherapy and herceptin?

A. The breast cancer treatment mainly focus on the removal of cancer cells and further treatment to prevent its occurance in future. Generally herceptin is the treatment given to destroy cancer cells which have high level of HER2 protein. And chemotherapy is also given to kill cancer cells, which again depends on the type & stage of cancer cells. Herceptin may have the side effects of severe anemia and nausea/ vomiting. Chemotherapy will also have the side effect such as vomiting, hair loss, fatigue, diarrhea, some infections, anemia, swellings, soreness, joint ache. But there is nothing to worry as this is the only treatment available for cancer.

More discussions about Herceptin
References in periodicals archive ?
Results showed that the risk of death was reduced by 34 percent for people who received Perjeta, Herceptin and chemotherapy, compared to those who received Herceptin and chemotherapy (HR=0.
It will be important for Roche to demonstrate how Herceptin can be differentiated from non-innovator Herceptin in China," said Decision Resources Analyst Kwok-fai Ng, M.
The injection of Herceptin is now authorised for use in the UK after a licence was granted yesterday by the European Medicines Agency.
Food and Drug Administration (FDA) approved Perjeta in combination with Herceptin and docetaxel chemotherapy for the treatment of people with HER2-positive mBC, who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease, based on the results of the CLEOPATRA study.
Even if metastatic HER2-positive breast cancer initially responds to Herceptin, the disease usually eventually progresses on standard Herceptin-based therapy.
Jayne Sullivan, who was diagnosed with the disease almost five years ago, said Herceptin had given her the opportunity to get married, travel the world and see her children grow up.
I note Pharmac's advice that the 12-month course of Herceptin carries a greater risk of heart toxicity and that funding it would mean other drugs and treatments could not be provided.
The first study "dramatically shows that one should start with Herceptin and stay with Herceptin," Bill Burns, head of Roche's pharmaceuticals division, said.
The international study involved 156 patients who were randomly assigned Herceptin together with the chemotherapy drug capecitabine, or capecitabine alone.
The NeOAdjuvant Herceptin (NOAH) study results demonstrated that Herceptin plus chemotherapy completely eradicated the tumour (a pathological complete response to treatment) in nearly twice as many patients (43%), compared with only 23% of patients treated with chemotherapy alone.
In those studies, 87% of women treated with Herceptin plus the other chemotherapeutics were disease free after 3.
Doctors identified the 35-year-old, from Whickham, Gateshead, as among 20% of breast cancer patients for whom Herceptin could work.